• Home
  • Science
  • Therapeutic Strategy
  • dry AMD
  • Pipeline
  • Team
  • Contact Us
  • Publications
    • Home
    • Science
    • Therapeutic Strategy
    • dry AMD
    • Pipeline
    • Team
    • Contact Us
    • Publications
  • Home
  • Science
  • Therapeutic Strategy
  • dry AMD
  • Pipeline
  • Team
  • Contact Us
  • Publications
image4
image5

LEAD INDICATION: Age related macular Degeneration (AMD)

Macular Degeneration is the leading cause of irreversible blindness in the world.

Macular Degeneration is characterized by a loss of central vision.   There are two forms of Macular Degeneration "Dry" AMD and "Wet" AMD.  Approximately 90% of patients have Dry AMD.  Wet AMD can be treated with a class of drugs known as VEGF inhibitors.  There are currently no approved therapeutics for  Dry Macular Degeneration or the advanced stage of the disease known as Geographic Atrophy (GA).


A large and growing number of people are effected by AMD / Geographic Atrophy

There are more than 11 million individuals in the United States (US)  and > 196 million worldwide living with some degree of AMD. Worldwide there are 5 million people living with GA and almost everyone with AMD will develop GA over time.   

Role of PUFA in AMD

The underlying disease mechanism in dry AMD is controversial, nevertheless,  a significant body of data supports an important role for LC and VLC  PUFA.  In healthy retina,  LC and VLC  PUFA account for about 50 % - 70% of all fatty acids.   In aging humans and more notably in patients with AMD, levels of certain LC and VLC PUFA significantly decline. 

image6

Supporting Data: (ARPE-19 Cells)

ELOVL2 Regulates Levels of LC and VLC PUFA Associated with AMD

 Studies in human retinal pigmented epithelial cells (ARPE-19 Cells) demonstrate that knock down of ELOVL2 decreases the LC and VLC PUFA associated with aging and AMD.  Similarly, transduction of ARPE-19 cells with ELOVL2 significantly increases the same LC and VLC PUFA.   This  suggest that 1) the declining levels LC and VLC PUFA associated with aging and AMD are mediated by ELOVL2 and 2) that increasing ELOVL2 expression can rescue retinal cells from this pathology.    

image7

Supporting Data: ELOVL2 Functional Knock Out Mice

To demonstrate the role of ELOVL2 in AMD pathology, an experimental model "knocking-down" the expression of ELOVL2  was developed in mice [functional knock-out( FKO).    FKO mice showed  characteristic pathologies associated with AMD including: marked acceleration of drusen formation, complement infiltration (data not shown), and reduced scotopic response compared to  age matched wild type mice  (WT). 

image8

Supporting Data: De-methylation Therapy in Aged MiCE

Aged mice were treated with placebo or  demethylation therapy (shown as 5- Aza).  Following 12 weeks, the treated animals were tested for ERG response (Scotopic amplitude) and level of ELOVL2 gene expression.   Demethylation therapy significantly increased ELOVL2 expression and scotopic response.   These data suggest that restoration of ELOVL2 expression may slow or halt the decline of age related vision loss. 

image9
Find out more

Copyright © 2020 Visgenx, Inc. - All Rights Reserved.

Powered by GoDaddy